A venture capital arm of an Europe-headquartered bank invests in early-stage companies in the life science industry among other technologically oriented industries, and is looking to engage in late seed, Series A or Series B rounds. The initial investments typically range from 0.5M to 3M Euros. The firm is open to both leading and co-investing, and prefer to syndicate with other investors. The firm is primarily interested in companies based in Germany, Austria and Switzerland.
The firm is looking for new opportunities in the life science space including therapeutics, diagnostics, medical devices and digital health. The firm is interested in companies from pre-clinical to clinical stages onward, and would like to see some preclinical validations for therapeutics companies or prototypes for medical devices. The firm is opportunistic in terms of sector, subsectors and indications, and is open to considering orphan diseases.
The firm doesn’t have specific requirements for management teams. The firm is open to both leading and co-investing, and prefers to take a board seat when investing larger amounts.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment